Are B cells a potential target for therapeutic intervention in the classical T cell-mediated autoimmune disease type 1 diabetes?

Inflammation and Allergy - Drug Targets

Volumn 8, Issue 2, 2009, Pages 130-138

  Wållberg, Maja ^a   Green, Elizabeth A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; B CELL ACTIVATING FACTOR; BELIMUMAB; CD3 ANTIBODY; CD8 ANTIBODY; RITUXIMAB; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DAMAGE; CELL INTERACTION; CELL MATURATION; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG SCREENING; GENE STRUCTURE; GENETIC DISORDER; GENETIC PREDISPOSITION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE FUNCTION; MULTIPLE SCLEROSIS; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; TARGET CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; AUTOANTIGENS; B-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; ISLETS OF LANGERHANS; MICE; MICE, INBRED NOD; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 70349485141     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152809788462572     Document Type: Review

References (101)

1. Salomon, B.; Lenschow, D.J.; Rhee, L.; Ashourian, N.; Singh, B.; Sharpe, A.; Bluestone, J.A. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity, 2000, 12, 431-440.
2. Serra, P.; Amrani, A.; Yamanouchi, J.; Han, B.; Thiessen, S.; Utsugi, T.; Verdaguer, J.; Santamaria, P. CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells. Immunity, 2003, 19, 877-889.
3. Wong, F.S.; Siew, L.K.; Wen, L. CD8+ T-cells and their interaction with other cells in damage to islet beta-cells. Biochem. Soc. Trans., 2008, 36, 316-320.
4. Delovitch, T.L.; Singh, B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity, 1997, 7, 727-738.
5. Bonifacio, E.; Atkinson, M.; Eisenbarth, G.; Serreze, D.; Kay, T.W.; Lee-Chan, E.; Singh, B. International Workshop on Lessons From Animal Models for Human Type 1 Diabetes: identification of insulin but not glutamic acid decarboxylase or IA-2 as specific autoantigens of humoral autoimmunity in nonobese diabetic mice. Diabetes, 2001, 50, 2451-2458.
6. Yu, L.; Eisenbarth, G.S. Humoral autoimmunity. Adv. Exp. Med. Biol., 2004, 552, 247-267.
7. Serreze, D.V.; Fleming, S.A.; Chapman, H.D.; Richard, S.D.; Leiter, E.H.; Tisch, R.M. B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J. Immunol., 1998, 161, 3912-3918.
8. Martin, S.; Wolf-Eichbaum, D.; Duinkerken, G.; Scherbaum, W.A.; Kolb, H.; Noordzij, J.G.; Roep, B.O. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N. Engl. J. Med., 2001, 345, 1036-1040.
9. Willcox, A.; Richardson, S.J.; Bone, A.J.; Foulis, A.K.; Morgan, N.G. Analysis of islet inflammation in human type 1 diabetes. Clin. Exp. Immunol., 2009, 155, 173-181.
10. Greeley, S.A.; Katsumata, M.; Yu, L.; Eisenbarth, G.S.; Moore, D.J.; Goodarzi, H.; Barker, C.F.; Naji, A.; Noorchashm, H. Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice. Nat. Med., 2002, 8, 399-402.
11. Noorchashm, H.; Noorchashm, N.; Kern, J.; Rostami, S.Y.; Barker, C.F.; Naji, A. B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes, 1997, 46, 941-946.
12. Serreze, D.V.; Chapman, H.D.; Varnum, D.S.; Hanson, M.S.; Reifsnyder, P.C.; Richard, S.D.; Fleming, S.A.; Leiter, E.H.; Shultz, L.D. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice. J. Exp. Med., 1996, 184, 2049-2053.
13. Merrell, K.T.; Benschop, R.J.; Gauld, S.B.; Aviszus, K.; Decote-Ricardo, D.; Wysocki, L.J.; Cambier, J.C. Identification of anergic B cells within a wild-type repertoire. Immunity, 2006, 25, 953-962.
14. Nemazee, D. Does immunological tolerance explain the waste in the B-lymphocyte immune system? Experiment and theory. Ann. N.Y. Acad. Sci., 1995, 764, 397-401.
15. Shlomchik, M.J. Sites and stages of autoreactive B cell activation and regulation. Immunity, 2008, 28, 18-28.
16. Gay, D.; Saunders, T.; Camper, S.; Weigert, M. Receptor editing: an approach by autoreactive B cells to escape tolerance. J. Exp. Med., 1993, 177, 999-1008.
17. Goodnow, C.C.; Crosbie, J.; Adelstein, S.; Lavoie, T.B.; Smith-Gill, S.J.; Brink, R.A.; Pritchard-Briscoe, H.; Wotherspoon, J.S.; Loblay, R.H.; Raphael, K.; et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature, 1988, 334, 676-682.
18. Tiegs, S.L.; Russell, D.M.; Nemazee, D. Receptor editing in self-reactive bone marrow B cells. J. Exp. Med., 1993, 177, 1009-1020.
19. Fulcher, D.A.; Lyons, A.B.; Korn, S.L.; Cook, M.C.; Koleda, C.; Parish, C.; Fazekas de St Groth, B.; Basten, A. The fate of self-reactive B cells depends primarily on the degree of antigen receptor engagement and availability of T cell help. J. Exp. Med., 1996, 183, 2313-2328.
20. Hippen, K.L.; Schram, B.R.; Tze, L.E.; Pape, K.A.; Jenkins, M.K.; Behrens, T.W. In vivo assessment of the relative contributions of deletion, anergy, and editing to B cell self-tolerance. J. Immunol., 2005, 175, 909-916.
21. Gross, J.A.; Johnston, J.; Mudri, S.; Enselman, R.; Dillon, S.R.; Madden, K.; Xu, W.; Parrish-Novak, J.; Foster, D.; Lofton-Day, C.; Moore, M.; Littau, A.; Grossman, A.; Haugen, H.; Foley, K.; Blumberg, H.; Harrison, K.; Kindsvogel, W.; Clegg, C.H. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature, 2000, 404, 995-999.
22. Browning, J.L. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat. Rev. Drug Discov., 2006, 5, 564-576.
23. Silveira, P.A.; Dombrowsky, J.; Johnson, E.; Chapman, H.D.; Nemazee, D.; Serreze, D.V. B cell selection defects underlie the development of diabetogenic APCs in nonobese diabetic mice. J. Immunol., 2004, 172, 5086-5094.
24. Hussain, S.; Delovitch, T.L. Dysregulated B7-1 and B7-2 expression on nonobese diabetic mouse B cells is associated with increased T cell costimulation and the development of insulitis. J. Immunol., 2005, 174, 680-687.
25. Wheat, W.; Kupfer, R.; Gutches, D.G.; Rayat, G.R.; Beilke, J.; Scheinman, R.I.; Wegmann, D.R. Increased NF-kappa B activity in B cells and bone marrow-derived dendritic cells from NOD mice. Eur. J. Immunol., 2004, 34, 1395-1404.
26. Marino, E.; Batten, M.; Groom, J.; Walters, S.; Liuwantara, D.; Mackay, F.; Grey, S.T. Marginal-zone B-cells of nonobese diabetic mice expand with diabetes onset, invade the pancreatic lymph nodes, and present autoantigen to diabetogenic T-cells. Diabetes, 2008, 57, 395-404.
27. Attanavanich, K.; Kearney, J.F. Marginal zone, but not follicular B cells, are potent activators of naive CD4 T cells. J. Immunol., 2004, 172, 803-811.
28. Noorchashm, H.; Moore, D.J.; Lieu, Y.K.; Noorchashm, N.; Schlachterman, A.; Song, H.K.; Barker, C.F.; Naji, A. Contribution of the innate immune system to autoimmune diabetes: a role for the CR1/CR2 complement receptors. Cell Immunol., 1999, 195, 75-79.
29. Kumagai, Y.; Takeuchi, O.; Akira, S. TLR9 as a key receptor for the recognition of DNA. Adv. Drug Deliv. Rev., 2008, 60, 795-804.
30. Zipris, D.; Lien, E.; Nair, A.; Xie, J.X.; Greiner, D.L.; Mordes, J.P.; Rossini, A.A. TLR9-signaling pathways are involved in Kilham rat virus-induced autoimmune diabetes in the biobreeding diabetes-resistant rat. J. Immunol., 2007, 178, 693-701.
31. Silveira, P.A.; Grey, S.T. B cells in the spotlight: innocent bystanders or major players in the pathogenesis of type 1 diabetes. Trends Endocrinol. Metab., 2006, 17, 128-135.
32. Todd, J.A.; Wicker, L.S. Genetic protection from the inflammatory disease type 1 diabetes in humans and animal models. Immunity, 2001, 15, 387-395.
33. Wicker, L.S.; Clark, J.; Fraser, H.I.; Garner, V.E.; Gonzalez-Munoz, A.; Healy, B.; Howlett, S.; Hunter, K.; Rainbow, D.; Rosa, R.L.; Smink, L.J.; Todd, J.A.; Peterson, L.B. Type 1 diabetes genes and pathways shared by humans and NOD mice. J. Autoimmun., 2005, 25, 29-33.
34. Wicker, L.S.; Moule, C.L.; Fraser, H.; Penha-Goncalves, C.; Rainbow, D.; Garner, V.E.; Chamberlain, G.; Hunter, K.; Howlett, S.; Clark, J.; Gonzalez-Munoz, A.; Cumiskey, A.M.; Tiffen, P.; Howson, J.; Healy, B.; Smink, L.J.; Kingsnorth, A.; Lyons, P.A.; Gregory, S.; Rogers, J.; Todd, J.A.; Peterson, L.B. Natural genetic variants influencing type 1 diabetes in humans and in the NOD mouse. Novartis Found Symp., 2005, 267, 65-75.
35. Silveira, P.A.; Chapman, H.D.; Stolp, J.; Johnson, E.; Cox, S.L.; Hunter, K.; Wicker, L.S.; Serreze, D.V. Genes within the Idd5 and Idd9/ 11 diabetes susceptibility loci affect the pathogenic activity of B cells in nonobese diabetic mice. J. Immunol., 2006, 177, 7033-7041.
36. Sundstrom, M.; Lejon, K. Idd-linked genetic regulation of TACI-high expressing B cells in NOD mice. J. Autoimmun., 2007, 29, 116-124.
37. Ueda, H.; Howson, J.M.; Esposito, L.; Heward, J.; Snook, H.; Chamberlain, G.; Rainbow, D.B.; Hunter, K.M.; Smith, A.N.; Di Genova, G.; Herr, M.H.; Dahlman, I.; Payne, F.; Smyth, D.; Lowe, C.; Twells, R.C.; Howlett, S.; Healy, B.; Nutland, S.; Rance, H.E.; Everett, V.; Smink, L.J.; Lam, A.C.; Cordell, H.J.; Walker, N.M.; Bordin, C.; Hulme, J.; Motzo, C.; Cucca, F.; Hess, J.F.; Metzker, M.L.; Rogers, J.; Gregory, S.; Allahabadia, A.; Nithiyananthan, R.; Tuomilehto-Wolf, E.; Tuomilehto, J.;Bingley, P.; Gillespie, K.M.; Undlien, D.E.; Ronningen, K.S.; Guja, C.; Ionescu-Tirgoviste, C.; Savage, D.A.; Maxwell, A.P.; Carson, D.J.; Patterson, C.C.; Franklyn, J.A.; Clayton, D.G.; Peterson, L.B.; Wicker, L.S.; Todd, J.A.; Gough, S.C. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature, 2003, 423, 506-511.
38. Falcone, M.; Lee, J.; Patstone, G.; Yeung, B.; Sarvetnick, N.B lymphocytes are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD65 antigen in nonobese diabetic mice. J. Immunol., 1998, 161, 1163-1168.
39. Noorchashm, H.; Greeley, S.A.; Naji, A. The role of t/b lymphocyte collaboration in the regulation of autoimmune and alloimmune responses. Immunol. Res., 2003, 27, 443-450.
40. Noorchashm, H.; Moore, D.J.; Noto, L.E.; Noorchashm, N.; Reed, A.J.; Reed, A.L.; Song, H.K.; Mozaffari, R.; Jevnikar, A.M.; Barker, C.F.; Naji, A. Impaired CD4 T cell activation due to reliance upon B cell-mediated costimulation in nonobese diabetic (NOD) mice. J. Immunol., 2000, 165, 4685-4696.
41. Noorchashm, H.; Lieu, Y.K.; Noorchashm, N.; Rostami, S.Y.; Greeley, S.A.; Schlachterman, A.; Song, H.K.; Noto, L.E.; Jevnikar, A.M.; Barker, C.F.; Naji, A.I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet beta cells of nonobese diabetic mice. J. Immunol., 1999, 163, 743-750.
42. Ettinger, R.; Munson, S.H.; Chao, C.C.; Vadeboncoeur, M.; Toma, J.; McDevitt, H.O. A critical role for lymphotoxin-beta receptor in the development of diabetes in nonobese diabetic mice. J. Exp. Med., 2001, 193, 1333-1340.
43. Luzina, I.G.; Atamas, S.P.; Storrer, C.E.; daSilva, L.C.; Kelsoe, G.; Papadimitriou, J.C.; Handwerger, B.S. Spontaneous formation of germinal centers in autoimmune mice. J. Leukoc. Biol., 2001, 70, 578-584.
44. Hu, C.Y.; Rodriguez-Pinto, D.; Du, W.; Ahuja, A.; Henegariu, O.; Wong, F.S.; Shlomchik, M.J.; Wen, L. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Invest., 2007, 117, 3857-3867.
45. Sakaguchi, S.Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol., 2004, 22, 531-562.
46. Wang, B.; Gonzalez, A.; Benoist, C.; Mathis, D. The role of CD8+ T cells in the initiation of insulin-dependent diabetes mellitus. Eur. J. Immunol., 1996, 26, 1762-1769.
47. Kay, T.W.; Parker, J.L.; Stephens, L.A.; Thomas, H.E.; Allison, J. RIP-beta 2-microglobulin transgene expression restores insulitis, but not diabetes, in beta 2-microglobulin null nonobese diabetic mice. J. Immunol., 1996, 157, 3688-3693.
48. Serreze, D.V.; Gallichan, W.S.; Snider, D.P.; Croitoru, K.; Rosenthal, K.L.; Leiter, E.H.; Christianson, G.J.; Dudley, M.E.; Roopenian, D.C. MHC class I-mediated antigen presentation and induction of CD8+ cytotoxic T-cell responses in autoimmune diabetes-prone NOD mice. Diabetes, 1996, 45, 902-908.
49. Zuccato, E.; Blott, E.J.; Holt, O.; Sigismund, S.; Shaw, M.; Bossi, G.; Griffiths, G.M. Sorting of Fas ligand to secretory lysosomes is regulated by mono-ubiquitylation and phosphorylation. J. Cell Sci., 2007, 120, 191-199.
50. Wong, F.S.; Karttunen, J.; Dumont, C.; Wen, L.; Visintin, I.; Pilip, I.M.; Shastri, N.; Pamer, E.G.; Janeway, C.A., Jr. Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat. Med., 1999, 5, 1026-1031.
51. Lieberman, S.M.; Evans, A.M.; Han, B.; Takaki, T.; Vinnitskaya, Y.; Caldwell, J.A.; Serreze, D.V.; Shabanowitz, J.; Hunt, D.F.; Nathenson, S.G.; Santamaria, P.; DiLorenzo, T.P. Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes. Proc. Natl. Acad. Sci. USA, 2003, 100, 8384-8388.
52. Quinn, A.; McInerney, M.F.; Sercarz, E.E. MHC class I-restricted determinants on the glutamic acid decarboxylase 65 molecule induce spontaneous CTL activity. J. Immunol., 2001, 167, 1748-1757.
53. Krishnamurthy, B.; Mariana, L.; Gellert, S.A.; Colman, P.G.; Harrison, L.C.; Lew, A.M.; Santamaria, P.; Thomas, H.E.; Kay, T.W. Autoimmunity to both proinsulin and IGRP is required for diabetes in nonobese diabetic 8.3 TCR transgenic mice. J. Immunol., 2008, 180, 4458-4464.
54. Bottazzo, G.F.; Dean, B.M.; McNally, J.M.; MacKay, E.H.; Swift, P.G.; Gamble, D.R. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N. Engl. J. Med., 1985, 313, 353-360.
55. Hassainya, Y.; Garcia-Pons, F.; Kratzer, R.; Lindo, V.; Greer, F.; Lemonnier, F.A.; Niedermann, G.; van Endert, P.M. Identification of naturally processed HLA-A2 - restricted proinsulin epitopes by reverse immunology. Diabetes, 2005, 54, 2053-2059.
56. Ouyang, Q.; Standifer, N.E.; Qin, H.; Gottlieb, P.; Verchere, C.B.; Nepom, G.T.; Tan, R.; Panagiotopoulos, C. Recognition of HLA class I-restricted beta-cell epitopes in type 1 diabetes. Diabetes, 2006, 55, 3068-3074.
57. Panina-Bordignon, P.; Lang, R.; van Endert, P.M.; Benazzi, E.; Felix, A.M.; Pastore, R.M.; Spinas, G.A.; Sinigaglia, F. Cytotoxic T cells specific for glutamic acid decarboxylase in autoimmune diabetes. J. Exp. Med., 1995, 181, 1923-1927.
58. Sibley, R.K.; Sutherland, D.E.; Goetz, F.; Michael, A.F. Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Lab. Invest., 1985, 53, 132-144.
59. Amrani, A.; Serra, P.; Yamanouchi, J.; Trudeau, J.D.; Tan, R.; Elliott, J.F.; Santamaria, P. Expansion of the antigenic repertoire of a single T cell receptor upon T cell activation. J. Immunol., 2001, 167, 655-666.
60. Amrani, A.; Verdaguer, J.; Serra, P.; Tafuro, S.; Tan, R.; Santamaria, P. Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature, 2000, 406, 739-742.
61. Bennett, S.R.; Carbone, F.R.; Toy, T.; Miller, J.F.; Heath, W.R. B cells directly tolerize CD8(+) T cells. J. Exp. Med., 1998, 188, 1977-1983.
62. Diaz-de-Durana, Y.; Mantchev, G.T.; Bram, R.J.; Franco, A. TACI-BLyS signaling via B-cell-dendritic cell cooperation is required for naive CD8+ T-cell priming in vivo. Blood, 2006, 107, 594-601.
63. Zeng, R.; Spolski, R.; Finkelstein, S.E.; Oh, S.; Kovanen, P.E.; Hinrichs, C.S.; Pise-Masison, C.A.; Radonovich, M.F.; Brady, J.N.; Restifo, N.P.; Berzofsky, J.A.; Leonard, W.J. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J. Exp. Med., 2005, 201, 139-148.
64. Harbers, S.O.; Crocker, A.; Catalano, G.; D'Agati, V.; Jung, S.; Desai, D.D.; Clynes, R. Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance. J. Clin. Invest., 2007, 117, 1361-1369.
65. Green, E.A.; Flavell, R.A. Tumor necrosis factor-alpha and the progression of diabetes in non-obese diabetic mice. Immunol. Rev., 1999, 169, 11-22.
66. Green, E.A.; Eynon, E.E.; Flavell, R.A. Local expression of TNFalpha in neonatal NOD mice promotes diabetes by enhancing presentation of islet antigens. Immunity, 1998, 9, 733-743.
67. Green, E.A.; Wong, F.S.; Eshima, K.; Mora, C.; Flavell, R.A. Neonatal tumor necrosis factor alpha promotes diabetes in nonobese diabetic mice by CD154-independent antigen presentation to CD8(+) T cells. J. Exp. Med., 2000, 191, 225-238.
68. Brodie, G.M.; Wallberg, M.; Santamaria, P.; Wong, F.S.; Green, E.A. B-cells promote intra-islet CD8+ cytotoxic T-cell survival to enhance type 1 diabetes. Diabetes, 2008, 57, 909-917.
69. Asano, M.S.; Ahmed, R. CD8 T cell memory in B cell-deficient mice. J. Exp. Med., 1996, 183, 2165-2174.
70. Takahashi, C.; Mittler, R.S.; Vella, A.T. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J. Immunol., 1999, 162, 5037- 5040.
71. Gray, J.C.; French, R.R.; James, S.; Al-Shamkhani, A.; Johnson, P.W.; Glennie, M.J. Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies. Eur. J. Immunol., 2008, 38, 2499-2511.
72. Muller, D.; Frey, K.; Kontermann, R.E. A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy. J. Immunother., 2008, 31, 714-722.
73. Harrison, J.M.; Bertram, E.M.; Boyle, D.B.; Coupar, B.E.; Ranasinghe, C.; Ramshaw, I. A. 4-1BBL coexpression enhances HIV-specific CD8 T cell memory in a poxvirus prime-boost vaccine. Vaccine, 2006, 24, 6867-6874.
74. Pulle, G.; Vidric, M.; Watts, T. H. IL-15-dependent induction of 4-1BB promotes antigen-independent CD8 memory T cell survival. J. Immunol., 2006, 176, 2739-2748.
75. Asai, T.; Choi, B.K.; Kwon, P.M.; Kim, W.Y.; Kim, J.D.; Vinay, D.S.; Gebhardt, B.M.; Kwon, B.S. Blockade of the 4-1BB (CD137)/4-1BBL and/or CD28/CD80/CD86 costimulatory pathways promotes corneal allograft survival in mice. Immunology, 2007, 121, 349-358.
76. Huang, B.J.; Yin, H.; Huang, Y.F.; Xu, J.F.; Xiong, P.; Feng, W.; Zheng, F.; Xu, Y.; Fang, M.; Gong, F.L. Gene therapy using adenoviral vector encoding 4-1BBIg gene significantly prolonged murine cardiac allograft survival. Transpl. Immunol., 2006, 16, 88-94.
77. Lyons, P.A.; Hancock, W.W.; Denny, P.; Lord, C.J.; Hill, N.J.; Armitage, N.; Siegmund, T.; Todd, J.A.; Phillips, M.S.; Hess, J.F.; Chen, S.L.; Fischer, P.A.; Peterson, L.B.; Wicker, L.S. The NOD Idd9 genetic interval influences the pathogenicity of insulitis and contains molecular variants of Cd30, Tnfr2, and Cd137. Immunity, 2000, 13, 107-115.
78. Chamberlain, G.; Wallberg, M.; Rainbow, D.; Hunter, K.; Wicker, L.S.; Green, E.A. A 20-Mb region of chromosome 4 controls TNFalpha-mediated CD8+ T cell aggression toward beta cells in type 1 diabetes. J. Immunol., 2006, 177, 5105-5114.
79. Sytwu, H.K.; Lin, W.D.; Roffler, S.R.; Hung, J.T.; Sung, H.S.; Wang, C.H.; Cheng, T.L.; Tsou, S.C.; Hsi, S.C.; Shen, K.L. Anti-4-1BB-based immunotherapy for autoimmune diabetes: lessons from a transgenic non-obese diabetic (NOD) model. J. Autoimmun., 2003, 21, 247-254.
80. Deola, S.; Panelli, M.C.; Maric, D.; Selleri, S.; Dmitrieva, N.I.; Voss, C.Y.; Klein, H.; Stroncek, D.; Wang, E.; Marincola, F.M. Helper B cells promote cytotoxic T cell survival and proliferation independently of antigen presentation through CD27/CD70 interactions. J. Immunol., 2008, 180, 1362-1372.
81. St Clair, E.W.; Turka, L.A.; Saxon, A.; Matthews, J.B.; Sayegh, M.H.; Eisenbarth, G.S.; Bluestone, J. New reagents on the horizon for immune tolerance. Annu. Rev. Med., 2007, 58, 329-346.
82. Chatenoud, L.; Bluestone, J.A. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat. Rev. Immunol., 2007, 7, 622-632.
83. Belghith, M.; Bluestone, J.A.; Barriot, S.; Megret, J.; Bach, J.F.; Chatenoud, L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med., 2003, 9, 1202-1208.
84. Bolt, S.; Routledge, E.; Lloyd, I.; Chatenoud, L.; Pope, H.; Gorman, S.D.; Clark, M.; Waldmann, H. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur. J. Immunol., 1993, 23, 403-411.
85. Herold, K.C.; Gitelman, S.E.; Masharani, U.; Hagopian, W.; Bisikirska, B.; Donaldson, D.; Rother, K.; Diamond, B.; Harlan, D.M.; Bluestone, J.A. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes, 2005, 54, 1763-1769.
86. Xu, D.; Alegre, M.L.; Varga, S.S.; Rothermel, A.L.; Collins, A.M.; Pulito, V.L.; Hanna, L.S.; Dolan, K.P.; Parren, P.W.; Bluestone, J.A.; Jolliffe, L.K.; Zivin, R.A. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol., 2000, 200, 16-26.
87. Silverman, G.J.; Weisman, S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum., 2003, 48, 1484-1492.
88. Edwards, J.C.; Szczepanski, L.; Szechinski, J.; Filipowicz-Sosnowska, A.; Emery, P.; Close, D.R.; Stevens, R.M.; Shaw, T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med., 2004, 350, 2572-2581.
89. Lopez-Diego, R.S.; Weiner, H.L. Novel therapeutic strategies for multiple sclerosis - a multifaceted adversary. Nat. Rev. Drug. Discov., 2008, 7, 909-925.
90. Cambridge, G.; Stohl, W.; Leandro, M.J.; Migone, T.S.; Hilbert, D.M.; Edwards, J.C. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum., 2006, 54, 723-732.
91. Yazawa, N.; Hamaguchi, Y.; Poe, J.C.; Tedder, T.F. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc. Natl. Acad. Sci. USA, 2005, 102, 15178-15183.
92. Zekavat, G.; Rostami, S.Y.; Badkerhanian, A.; Parsons, R.F.; Koeberlein, B.; Yu, M.; Ward, C.D.; Migone, T.S.; Yu, L.; Eisenbarth, G.S.; Cancro, M.P.; Naji, A.; Noorchashm, H. In vivo BLyS/BAFF neutralization ameliorates islet-directed autoimmunity in nonobese diabetic mice. J. Immunol., 2008, 181, 8133-8144.
93. Wolf, S.D.; Dittel, B.N.; Hardardottir, F.; Janeway, C.A., Jr. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J. Exp. Med., 1996, 184, 2271-2278.
94. Tedder, T.F.; Inaoki, M.; Sato, S. The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity, 1997, 6, 107-118.
95. Matsushita, T.; Fujimoto, M.; Hasegawa, M.; Komura, K.; Takehara, K.; Tedder, T.F.; Sato, S. Inhibitory role of CD19 in the progression of experimental autoimmune encephalomyelitis by regulating cytokine response. Am. J. Pathol., 2006, 168, 812-821.
96. Fillatreau, S.; Sweenie, C.H.; McGeachy, M.J.; Gray, D.; Anderton, S.M. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol., 2002, 3, 944-950.
97. Bouaziz, J.D.; Yanaba, K.; Tedder, T.F. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol. Rev., 2008, 224, 201-214.
98. Hussain, S.; Delovitch, T.L. Intravenous transfusion of BCR-activated B cells protects NOD mice from type 1 diabetes in an IL-10-dependent manner. J. Immunol., 2007, 179, 7225-7232.
99. Soukhareva, N.; Jiang, Y.; Scott, D.W. Treatment of diabetes in NOD mice by gene transfer of Ig-fusion proteins into B cells: role of T regulatory cells. Cell Immunol., 2006, 240, 41-46.
100. Wasserfall, C.H.; Atkinson, M.A. Autoantibody markers for the diagnosis and prediction of type 1 diabetes. Autoimmun. Rev., 2006, 5, 424-428.
101. Xiu, Y.; Wong, C.P.; Bouaziz, J.D.; Hamaguchi, Y.; Wang, Y.; Pop, S.M.; Tisch, R.M.; Tedder, T.F. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions. J. Immunol., 2008, 180, 2863-2875.